JP2020023529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020023529A5 JP2020023529A5 JP2019186168A JP2019186168A JP2020023529A5 JP 2020023529 A5 JP2020023529 A5 JP 2020023529A5 JP 2019186168 A JP2019186168 A JP 2019186168A JP 2019186168 A JP2019186168 A JP 2019186168A JP 2020023529 A5 JP2020023529 A5 JP 2020023529A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- phenylcyclopropyl
- piperidin
- azetidin
- acetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 51
- -1 4-fluorophenylmethyl Chemical group 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 201000011510 cancer Diseases 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- 239000011780 sodium chloride Substances 0.000 claims 18
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 208000009956 Adenocarcinoma Diseases 0.000 claims 8
- 229940079593 drugs Drugs 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 6
- 108010001645 Rituximab Proteins 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 6
- 229960004641 rituximab Drugs 0.000 claims 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 5
- 229960005420 Etoposide Drugs 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010025310 Other lymphomas Diseases 0.000 claims 5
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 5
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 206010016629 Fibroma Diseases 0.000 claims 4
- 206010024612 Lipoma Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000001756 Virus Disease Diseases 0.000 claims 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 201000011066 hemangioma Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 3
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 3
- 206010027191 Meningioma Diseases 0.000 claims 3
- 206010028537 Myelofibrosis Diseases 0.000 claims 3
- 208000003476 Primary Myelofibrosis Diseases 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 201000008808 fibrosarcoma Diseases 0.000 claims 3
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 3
- 201000008968 osteosarcoma Diseases 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 3
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- 206010001019 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- XVOKNSJVLHJVLS-ZWKOTPCHSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CNC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CNC1)CC#N XVOKNSJVLHJVLS-ZWKOTPCHSA-N 0.000 claims 2
- XZDHATBCLTUCFX-RBUKOAKNSA-N CN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N XZDHATBCLTUCFX-RBUKOAKNSA-N 0.000 claims 2
- BBEZPWPHOQIEGI-FCHUYYIVSA-N CN1N=CC(=C1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CN1N=CC(=C1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N BBEZPWPHOQIEGI-FCHUYYIVSA-N 0.000 claims 2
- WKZYPDVFDYESLQ-RBUKOAKNSA-N CS(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CS(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N WKZYPDVFDYESLQ-RBUKOAKNSA-N 0.000 claims 2
- 208000002458 Carcinoid Tumor Diseases 0.000 claims 2
- 206010007275 Carcinoid tumour Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 208000002047 Essential Thrombocythemia Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000002927 Hamartoma Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 206010024190 Leiomyosarcomas Diseases 0.000 claims 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 208000005749 Leukemia, Promyelocytic, Acute Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N Panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000008696 Polycythemia Vera Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 206010043276 Teratoma Diseases 0.000 claims 2
- 229960000237 Vorinostat Drugs 0.000 claims 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 2
- 208000008383 Wilms Tumor Diseases 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 201000003076 angiosarcoma Diseases 0.000 claims 2
- STIUWSWFXIBBKI-UHFFFAOYSA-N azetidine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCC1 STIUWSWFXIBBKI-UHFFFAOYSA-N 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 229960001467 bortezomib Drugs 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- 201000009030 carcinoma Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 201000004404 neurofibroma Diseases 0.000 claims 2
- 229960005184 panobinostat Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- UOZODPSAJZTQNH-QGSSWKKLSA-N (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R)-5-[(1R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)C(O[C@H]2C([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-QGSSWKKLSA-N 0.000 claims 1
- OHJKXVLJWUPWQG-IUYNYSEKSA-J (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate Chemical compound O[C@@H]1C(NS([O-])(=O)=O)C(O)O[C@H](COS([O-])(=O)=O)C1O[C@H]1C(OS([O-])(=O)=O)[C@@H](O)C(O)C(C([O-])=O)O1 OHJKXVLJWUPWQG-IUYNYSEKSA-J 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 1
- VZIHTQKMHLOIII-UHFFFAOYSA-N 3,5-dihydro-2H-furan Chemical group [CH]1CCOC1 VZIHTQKMHLOIII-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 229940035674 ANESTHETICS Drugs 0.000 claims 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 229960003272 ASPARAGINASE Drugs 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 108010090838 Alemtuzumab Proteins 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N Antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 102000015790 Asparaginase Human genes 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 229960002756 Azacitidine Drugs 0.000 claims 1
- 229960003071 Bacitracin Drugs 0.000 claims 1
- 108010001478 Bacitracin Proteins 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 108010005144 Bevacizumab Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 229960001561 Bleomycin Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- VUGJEBCUYKUMNE-BJKOFHAPSA-N C(#N)C=1C=C(C(=O)O)C=CC1N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound C(#N)C=1C=C(C(=O)O)C=CC1N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N VUGJEBCUYKUMNE-BJKOFHAPSA-N 0.000 claims 1
- PWIOSBYHMSARTI-LOSJGSFVSA-N C(#N)CC1(CN(C1)C1=C(C#N)C=CC=C1)N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)C1=C(C#N)C=CC=C1)N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 PWIOSBYHMSARTI-LOSJGSFVSA-N 0.000 claims 1
- WAOKAHCYIMPPGD-BJKOFHAPSA-N C(#N)CC1(CN(C1)C1=C(C#N)C=CC=C1)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)C1=C(C#N)C=CC=C1)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 WAOKAHCYIMPPGD-BJKOFHAPSA-N 0.000 claims 1
- CTZRQHBOAPYTEO-BJKOFHAPSA-N C(#N)CC1(CN(C1)C1=C(C#N)C=CC=N1)N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)C1=C(C#N)C=CC=N1)N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 CTZRQHBOAPYTEO-BJKOFHAPSA-N 0.000 claims 1
- JDCIQSZZZCQWTA-XZOQPEGZSA-N C(#N)CC1(CN(C1)C1=C(C#N)C=CC=N1)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)C1=C(C#N)C=CC=N1)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 JDCIQSZZZCQWTA-XZOQPEGZSA-N 0.000 claims 1
- SIOQWJTYOGOHDJ-WNCULLNHSA-N C(#N)CC1(CN(C1)C1=CC(=C(C(=O)NC(C)C)C=C1F)F)N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)C1=CC(=C(C(=O)NC(C)C)C=C1F)F)N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 SIOQWJTYOGOHDJ-WNCULLNHSA-N 0.000 claims 1
- LDQZIOZDTIHCGW-IZZNHLLZSA-N C(#N)CC1(CN(C1)C1=CC=C(C#N)C=C1)N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)C1=CC=C(C#N)C=C1)N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 LDQZIOZDTIHCGW-IZZNHLLZSA-N 0.000 claims 1
- CVXHLUSQNWCTAM-LOSJGSFVSA-N C(#N)CC1(CN(C1)C1=CC=C(C#N)C=C1)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)C1=CC=C(C#N)C=C1)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 CVXHLUSQNWCTAM-LOSJGSFVSA-N 0.000 claims 1
- KLWGXIYQXBIWJD-VQTJNVASSA-N C(#N)CC1(CN(C1)CC(=O)NC)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)CC(=O)NC)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 KLWGXIYQXBIWJD-VQTJNVASSA-N 0.000 claims 1
- RWNJNROHWPRAPM-VQTJNVASSA-N C(#N)CC1(CN(C1)CCC(=O)O)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(#N)CC1(CN(C1)CCC(=O)O)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 RWNJNROHWPRAPM-VQTJNVASSA-N 0.000 claims 1
- CHLWPXFUYDMJHJ-VQTJNVASSA-N C(C)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound C(C)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N CHLWPXFUYDMJHJ-VQTJNVASSA-N 0.000 claims 1
- JIGFNRMEKAMQDW-LEWJYISDSA-N C(C)(=O)N1CCC(CC1)(N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound C(C)(=O)N1CCC(CC1)(N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N JIGFNRMEKAMQDW-LEWJYISDSA-N 0.000 claims 1
- CBQUUHSDOMDECC-RBUKOAKNSA-N C(C)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)O Chemical compound C(C)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)O CBQUUHSDOMDECC-RBUKOAKNSA-N 0.000 claims 1
- JGILOSZKUGHPOT-LEWJYISDSA-N C(C)S(=O)(=O)N1CC(C1)(N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound C(C)S(=O)(=O)N1CC(C1)(N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N JGILOSZKUGHPOT-LEWJYISDSA-N 0.000 claims 1
- UOUIRRWHFRPORZ-VQTJNVASSA-N C(C)S(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound C(C)S(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N UOUIRRWHFRPORZ-VQTJNVASSA-N 0.000 claims 1
- NKPUMNAEPKDNKZ-VQTJNVASSA-N C(C)S(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CCO Chemical compound C(C)S(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CCO NKPUMNAEPKDNKZ-VQTJNVASSA-N 0.000 claims 1
- DYHJMPPSZFIVIQ-LOSJGSFVSA-N C(C1=CC=CC=C1)(=O)N1CC(C1)(N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound C(C1=CC=CC=C1)(=O)N1CC(C1)(N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N DYHJMPPSZFIVIQ-LOSJGSFVSA-N 0.000 claims 1
- QXXWMQDZVMZJOV-BJKOFHAPSA-N C(C1=CC=CC=C1)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound C(C1=CC=CC=C1)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N QXXWMQDZVMZJOV-BJKOFHAPSA-N 0.000 claims 1
- YIVORPSROJSZLH-LOSJGSFVSA-N C(C1=CC=CC=C1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound C(C1=CC=CC=C1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N YIVORPSROJSZLH-LOSJGSFVSA-N 0.000 claims 1
- XVOKNSJVLHJVLS-MSOLQXFVSA-N C1(=CC=CC=C1)[C@@H]1[C@H](C1)NC1CCN(CC1)C1(CNC1)CC#N Chemical compound C1(=CC=CC=C1)[C@@H]1[C@H](C1)NC1CCN(CC1)C1(CNC1)CC#N XVOKNSJVLHJVLS-MSOLQXFVSA-N 0.000 claims 1
- GHEGXJMODHODMQ-RBUKOAKNSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CCC1)CC#N GHEGXJMODHODMQ-RBUKOAKNSA-N 0.000 claims 1
- DAGXBMVVNPMYCV-PZJWPPBQSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1=CC=NN1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1=CC=NN1)CC#N DAGXBMVVNPMYCV-PZJWPPBQSA-N 0.000 claims 1
- XGFPOLXECPYKPJ-VQTJNVASSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1=CN=CS1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1=CN=CS1)CC#N XGFPOLXECPYKPJ-VQTJNVASSA-N 0.000 claims 1
- HGTYIFDNJSWEGV-LEWJYISDSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1=NC=CN=C1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1=NC=CN=C1)CC#N HGTYIFDNJSWEGV-LEWJYISDSA-N 0.000 claims 1
- PNLVAMICRIAANP-YPURBLFUSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1COCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1COCC1)CC#N PNLVAMICRIAANP-YPURBLFUSA-N 0.000 claims 1
- BMNSVVYABBFIOM-UGGDCYSXSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1OCCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C1OCCC1)CC#N BMNSVVYABBFIOM-UGGDCYSXSA-N 0.000 claims 1
- TYHVLCMAEMDYCP-LEWJYISDSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C=1C=NNC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C=1C=NNC1)CC#N TYHVLCMAEMDYCP-LEWJYISDSA-N 0.000 claims 1
- UMLNPHYCWGBJOH-VQTJNVASSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C=1N=CSC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C=1N=CSC1)CC#N UMLNPHYCWGBJOH-VQTJNVASSA-N 0.000 claims 1
- DEVUVKQKULAJNV-VQTJNVASSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C=1SC=CN1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)C=1SC=CN1)CC#N DEVUVKQKULAJNV-VQTJNVASSA-N 0.000 claims 1
- PNLVAMICRIAANP-ILWGZMRPSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)[C@@H]1COCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)[C@@H]1COCC1)CC#N PNLVAMICRIAANP-ILWGZMRPSA-N 0.000 claims 1
- BMNSVVYABBFIOM-BHDDXSALSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)[C@@H]1OCCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)[C@@H]1OCCC1)CC#N BMNSVVYABBFIOM-BHDDXSALSA-N 0.000 claims 1
- PNLVAMICRIAANP-BAGYTPMASA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)[C@H]1COCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)[C@H]1COCC1)CC#N PNLVAMICRIAANP-BAGYTPMASA-N 0.000 claims 1
- BMNSVVYABBFIOM-BDTNDASRSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)[C@H]1OCCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(=O)[C@H]1OCCC1)CC#N BMNSVVYABBFIOM-BDTNDASRSA-N 0.000 claims 1
- FMBNWGHWIFUXPF-BJKOFHAPSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(CC1=NC=CC=C1)=O)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C(CC1=NC=CC=C1)=O)CC#N FMBNWGHWIFUXPF-BJKOFHAPSA-N 0.000 claims 1
- SRPFBOAHKKBKKR-XZOQPEGZSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C1CCOCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C1CCOCC1)CC#N SRPFBOAHKKBKKR-XZOQPEGZSA-N 0.000 claims 1
- FXFHNEHARADBNL-JTGIGXABSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C1COCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C1COCC1)CC#N FXFHNEHARADBNL-JTGIGXABSA-N 0.000 claims 1
- GHWJMOSGGHRPOZ-LEWJYISDSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC1=CN=CS1)CC(=O)O Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC1=CN=CS1)CC(=O)O GHWJMOSGGHRPOZ-LEWJYISDSA-N 0.000 claims 1
- PAODTXXDMLQHCY-LEWJYISDSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC1=NC=CC=N1)CC(=O)O Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC1=NC=CC=N1)CC(=O)O PAODTXXDMLQHCY-LEWJYISDSA-N 0.000 claims 1
- NLKWZDUQUSVPJL-FCHUYYIVSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC=1C=NC=NC1)CC(=O)O Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC=1C=NC=NC1)CC(=O)O NLKWZDUQUSVPJL-FCHUYYIVSA-N 0.000 claims 1
- WDRHLTOXVSBNJN-LEWJYISDSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC=1N=CSC1)CC(=O)O Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC=1N=CSC1)CC(=O)O WDRHLTOXVSBNJN-LEWJYISDSA-N 0.000 claims 1
- USUWNBOZHLVEAO-VQTJNVASSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC=1SC=CN1)CC(=O)O Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CC=1SC=CN1)CC(=O)O USUWNBOZHLVEAO-VQTJNVASSA-N 0.000 claims 1
- WQPGXBJNMQFZEF-RBUKOAKNSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CCC(F)(F)F)CC(=O)O Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)CCC(F)(F)F)CC(=O)O WQPGXBJNMQFZEF-RBUKOAKNSA-N 0.000 claims 1
- RRYIYTAJBSSOPL-VQTJNVASSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CCC1)CC#N RRYIYTAJBSSOPL-VQTJNVASSA-N 0.000 claims 1
- ATMPNNXKBAQDJV-RBUKOAKNSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CCC1)CC(=O)O Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CCC1)CC(=O)O ATMPNNXKBAQDJV-RBUKOAKNSA-N 0.000 claims 1
- ITMDMKOHSAXUAX-XZOQPEGZSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CN(C1)C1=NC=C(C=C1)C(F)(F)F)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CN(C1)C1=NC=C(C=C1)C(F)(F)F)CC#N ITMDMKOHSAXUAX-XZOQPEGZSA-N 0.000 claims 1
- TUXVOJPDNKEUES-JTHBVZDNSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CN(C1)C1=NC=CC=C1C(F)(F)F)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CN(C1)C1=NC=CC=C1C(F)(F)F)CC#N TUXVOJPDNKEUES-JTHBVZDNSA-N 0.000 claims 1
- SFXSOHVWLSFZFW-RBUKOAKNSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CNC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CNC1)CC#N SFXSOHVWLSFZFW-RBUKOAKNSA-N 0.000 claims 1
- DOMHYKFZPPFFSW-ZWKOTPCHSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CNC1)CC(=O)O Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CCN(CC1)C1(CNC1)CC(=O)O DOMHYKFZPPFFSW-ZWKOTPCHSA-N 0.000 claims 1
- MOKIPZSEHIRCHU-LOSJGSFVSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C1(CCN(CC1)S(=O)(=O)C1=CC=CC=C1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C1(CCN(CC1)S(=O)(=O)C1=CC=CC=C1)CC#N MOKIPZSEHIRCHU-LOSJGSFVSA-N 0.000 claims 1
- IADKUDSGXJARPU-RBUKOAKNSA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C1(CCNCC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C1(CCNCC1)CC#N IADKUDSGXJARPU-RBUKOAKNSA-N 0.000 claims 1
- UXIYDZIOOUEJGJ-DLBZAZTESA-N C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C1(CNC1)CC#N Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C1(CNC1)CC#N UXIYDZIOOUEJGJ-DLBZAZTESA-N 0.000 claims 1
- POXDXBWDCJXXQK-FCHUYYIVSA-N C1(CC1)CN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)NC Chemical compound C1(CC1)CN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)NC POXDXBWDCJXXQK-FCHUYYIVSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- ZQLIYVSBBTXGFL-RBUKOAKNSA-N CC1(CCN(CC1)C1(CCC1)CC(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound CC1(CCN(CC1)C1(CCC1)CC(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ZQLIYVSBBTXGFL-RBUKOAKNSA-N 0.000 claims 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N CHEMBL1615438 Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims 1
- LHGCYQPQMMRWBE-VQTJNVASSA-N CN1CC(C1)(N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CN1CC(C1)(N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N LHGCYQPQMMRWBE-VQTJNVASSA-N 0.000 claims 1
- UUFGEUMETGJRQR-ZWKOTPCHSA-N CN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)O Chemical compound CN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)O UUFGEUMETGJRQR-ZWKOTPCHSA-N 0.000 claims 1
- FDRSPKPJWQDXPR-VQTJNVASSA-N CN1CCC(CC1)(N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CN1CCC(CC1)(N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N FDRSPKPJWQDXPR-VQTJNVASSA-N 0.000 claims 1
- YSIRGVBHKRVSKU-FCHUYYIVSA-N CN1N=CC(=C1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CN1N=CC(=C1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N YSIRGVBHKRVSKU-FCHUYYIVSA-N 0.000 claims 1
- FTXZQOUPDXBLHA-FCHUYYIVSA-N CN1N=CC(=C1)S(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CN1N=CC(=C1)S(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N FTXZQOUPDXBLHA-FCHUYYIVSA-N 0.000 claims 1
- NQZHVXXBZTZCFM-LEWJYISDSA-N CN1N=CC=C1C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CN1N=CC=C1C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N NQZHVXXBZTZCFM-LEWJYISDSA-N 0.000 claims 1
- JDOVUIRQPWAANN-BJKOFHAPSA-N COC1CCN(CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound COC1CCN(CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N JDOVUIRQPWAANN-BJKOFHAPSA-N 0.000 claims 1
- NYIWGYPPKJPGTJ-VQTJNVASSA-N COCC1(CCN(CC1)C1(CCC1)CC(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound COCC1(CCN(CC1)C1(CCC1)CC(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 NYIWGYPPKJPGTJ-VQTJNVASSA-N 0.000 claims 1
- NBGAAOKBUAFGJO-RBUKOAKNSA-N CS(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CCO Chemical compound CS(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CCO NBGAAOKBUAFGJO-RBUKOAKNSA-N 0.000 claims 1
- NCGLLDRHTVMYPJ-VQTJNVASSA-N CS(=O)(=O)N1CCC(CC1)(N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound CS(=O)(=O)N1CCC(CC1)(N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N NCGLLDRHTVMYPJ-VQTJNVASSA-N 0.000 claims 1
- 229950009823 Calusterone Drugs 0.000 claims 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N Calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 claims 1
- 229960004117 Capecitabine Drugs 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 206010008263 Cervical dysplasia Diseases 0.000 claims 1
- 108010022830 Cetuximab Proteins 0.000 claims 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 Chlorambucil Drugs 0.000 claims 1
- 229960005091 Chloramphenicol Drugs 0.000 claims 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 1
- VFHTVJZMYGMJST-WIOPSUGQSA-N ClC1=C(C#N)C(=CC=C1)N1CC(C1)(N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound ClC1=C(C#N)C(=CC=C1)N1CC(C1)(N1CCC(CC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N VFHTVJZMYGMJST-WIOPSUGQSA-N 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims 1
- 229960001334 Corticosteroids Drugs 0.000 claims 1
- 229940009997 Cromolyn Drugs 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960000684 Cytarabine Drugs 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000640 Dactinomycin Drugs 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 229940018872 Dalteparin Sodium Drugs 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 229960000975 Daunorubicin Drugs 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- 229960003957 Dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960000605 Dexrazoxane Drugs 0.000 claims 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 206010062805 Dysplastic naevus Diseases 0.000 claims 1
- 229960002549 ENOXACIN Drugs 0.000 claims 1
- 229960001904 EPIRUBICIN Drugs 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N Enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 229960001433 Erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960001842 Estramustine Drugs 0.000 claims 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 1
- 208000005917 Exostosis Diseases 0.000 claims 1
- XEDHJJBMYHJZND-UKILVPOCSA-N FC1=C(C(=O)N2CC(C2)(N2CCC(CC2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=CC=C1 Chemical compound FC1=C(C(=O)N2CC(C2)(N2CCC(CC2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=CC=C1 XEDHJJBMYHJZND-UKILVPOCSA-N 0.000 claims 1
- QEODSRKCBHJXGW-LOSJGSFVSA-N FC1=CC=C(C(=O)N2CC(C2)(N2CCC(CC2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=C1 Chemical compound FC1=CC=C(C(=O)N2CC(C2)(N2CCC(CC2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=C1 QEODSRKCBHJXGW-LOSJGSFVSA-N 0.000 claims 1
- BSGNTEOUVKIDEX-LOSJGSFVSA-N FC1=CC=C(C(=O)N2CCC(CC2)(N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=C1 Chemical compound FC1=CC=C(C(=O)N2CCC(CC2)(N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=C1 BSGNTEOUVKIDEX-LOSJGSFVSA-N 0.000 claims 1
- MEHVWKKCGUIXNI-STTLMXHVSA-N FC1=CC=C(C=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C1CCC(CC1)O)CC#N Chemical compound FC1=CC=C(C=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C1CCC(CC1)O)CC#N MEHVWKKCGUIXNI-STTLMXHVSA-N 0.000 claims 1
- BWGRVHGXZYCISM-RBUKOAKNSA-N FC1=CC=C(C=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)S(=O)(=O)C)CC#N Chemical compound FC1=CC=C(C=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)S(=O)(=O)C)CC#N BWGRVHGXZYCISM-RBUKOAKNSA-N 0.000 claims 1
- INRMDSMOHQTQSG-LOSJGSFVSA-N FC1=CC=C(CC2(CCN(CC2)C2(CCC2)CC(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 Chemical compound FC1=CC=C(CC2(CCN(CC2)C2(CCC2)CC(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 INRMDSMOHQTQSG-LOSJGSFVSA-N 0.000 claims 1
- MJPVZDXQCTUQIG-LOSJGSFVSA-N FC=1C=C(C(=O)N2CC(C2)(N2CCC(CC2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=C(C1)F Chemical compound FC=1C=C(C(=O)N2CC(C2)(N2CCC(CC2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=C(C1)F MJPVZDXQCTUQIG-LOSJGSFVSA-N 0.000 claims 1
- JHBCJWXVGNIDCD-LOSJGSFVSA-N FC=1C=C(C(=O)N2CC(C2)(N2CCC(CC2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=CC1 Chemical compound FC=1C=C(C(=O)N2CC(C2)(N2CCC(CC2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=CC1 JHBCJWXVGNIDCD-LOSJGSFVSA-N 0.000 claims 1
- 208000007659 Fibroadenoma Diseases 0.000 claims 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
- 229960000961 Floxuridine Drugs 0.000 claims 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N Fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N Flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 229960002258 Fulvestrant Drugs 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960003297 Gemtuzumab ozogamicin Drugs 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 208000000527 Germinoma Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010018404 Glucagonoma Diseases 0.000 claims 1
- 229960003690 Goserelin Acetate Drugs 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 229940093912 Gynecological Sulfonamides Drugs 0.000 claims 1
- 206010019629 Hepatic adenoma Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000006359 Hepatoblastoma Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 229960003911 Histrelin acetate Drugs 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 229960000908 Idarubicin Drugs 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- 229960001101 Ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960003685 Imatinib mesylate Drugs 0.000 claims 1
- 206010022498 Insulinoma Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 210000001117 Keloid Anatomy 0.000 claims 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 229940089022 Leuprolide Acetate Drugs 0.000 claims 1
- 229960004338 Leuprorelin Drugs 0.000 claims 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N Levofloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims 1
- 206010024627 Liposarcoma Diseases 0.000 claims 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N Lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 1
- 229960004961 Mechlorethamine Drugs 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 229960004296 Megestrol Acetate Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N Mepacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 229960004469 Methoxsalen Drugs 0.000 claims 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- 229960000350 Mitotane Drugs 0.000 claims 1
- 229960001156 Mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 208000010492 Mucinous Cystadenocarcinoma Diseases 0.000 claims 1
- 206010028576 Myeloproliferative disease Diseases 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 208000009091 Myxoma Diseases 0.000 claims 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims 1
- GOBGZDUAYFOHAB-FCHUYYIVSA-N N1(CCOCC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound N1(CCOCC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N GOBGZDUAYFOHAB-FCHUYYIVSA-N 0.000 claims 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N Nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims 1
- 229960003255 Natamycin Drugs 0.000 claims 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N Natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims 1
- 229960000808 Netilmicin Drugs 0.000 claims 1
- 208000007538 Neurilemmoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 229960001180 Norfloxacin Drugs 0.000 claims 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N Norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims 1
- JQXXHWHPUNPDRT-ZNQWNCHJSA-N O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-ZNQWNCHJSA-N 0.000 claims 1
- WNSIQTHQNNHKOU-VQTJNVASSA-N OC1(CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound OC1(CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N WNSIQTHQNNHKOU-VQTJNVASSA-N 0.000 claims 1
- TVDKZBASXPLLBZ-FCHUYYIVSA-N OC1(CCCC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound OC1(CCCC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N TVDKZBASXPLLBZ-FCHUYYIVSA-N 0.000 claims 1
- CFEZGDDEXODSOP-XZOQPEGZSA-N OC1CCN(CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound OC1CCN(CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N CFEZGDDEXODSOP-XZOQPEGZSA-N 0.000 claims 1
- ZPVKWJUILDIPIU-LEWJYISDSA-N OC1CN(C1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound OC1CN(C1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N ZPVKWJUILDIPIU-LEWJYISDSA-N 0.000 claims 1
- YGKRJKSCOHXOOF-VQTJNVASSA-N OCCN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound OCCN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N YGKRJKSCOHXOOF-VQTJNVASSA-N 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- LRISLSZFPGTNFP-TWDDROGUSA-N O[C@@H]1CC[C@H](CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound O[C@@H]1CC[C@H](CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N LRISLSZFPGTNFP-TWDDROGUSA-N 0.000 claims 1
- LNKLCUWGJGYEJN-NEWJYFPISA-N O[C@@H]1CC[C@H](CC1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound O[C@@H]1CC[C@H](CC1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N LNKLCUWGJGYEJN-NEWJYFPISA-N 0.000 claims 1
- LRISLSZFPGTNFP-KELGSRBJSA-N O[C@H]1CC[C@H](CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound O[C@H]1CC[C@H](CC1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N LRISLSZFPGTNFP-KELGSRBJSA-N 0.000 claims 1
- LNKLCUWGJGYEJN-UARRHKHWSA-N O[C@H]1CC[C@H](CC1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound O[C@H]1CC[C@H](CC1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N LNKLCUWGJGYEJN-UARRHKHWSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 229960001699 Ofloxacin Drugs 0.000 claims 1
- 208000008798 Osteoma Diseases 0.000 claims 1
- 102100013248 PIK3CD Human genes 0.000 claims 1
- 101710027435 PIK3CD Proteins 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 108010061219 Panitumumab Proteins 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 229960001373 Pegfilgrastim Drugs 0.000 claims 1
- 229960002340 Pentostatin Drugs 0.000 claims 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 1
- 241001503951 Phoma Species 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 claims 1
- 108010040201 Polymyxins Proteins 0.000 claims 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
- 229940079923 Quinacrine Drugs 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N RIFAMPICIN Chemical class O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 210000001525 Retina Anatomy 0.000 claims 1
- 208000005678 Rhabdomyoma Diseases 0.000 claims 1
- 229940081190 Rifampin Drugs 0.000 claims 1
- IIDCSONIAIQNMY-VQTJNVASSA-N S1N=CC=C1C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N Chemical compound S1N=CC=C1C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N IIDCSONIAIQNMY-VQTJNVASSA-N 0.000 claims 1
- 206010039667 Schwannoma Diseases 0.000 claims 1
- 208000004548 Serous Cystadenocarcinoma Diseases 0.000 claims 1
- 208000000097 Sertoli-Leydig Cell Tumor Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 229960005322 Streptomycin Drugs 0.000 claims 1
- 210000002536 Stromal Cells Anatomy 0.000 claims 1
- 229960004492 Suprofen Drugs 0.000 claims 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 claims 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 1
- 229960001603 Tamoxifen Drugs 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 229960001278 Teniposide Drugs 0.000 claims 1
- 208000001608 Teratocarcinoma Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 229940040944 Tetracyclines Drugs 0.000 claims 1
- 229960003433 Thalidomide Drugs 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 229960005454 Thioguanine Drugs 0.000 claims 1
- 229960001196 Thiotepa Drugs 0.000 claims 1
- 210000001685 Thyroid Gland Anatomy 0.000 claims 1
- 229960000707 Tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 206010044412 Transitional cell carcinoma Diseases 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- GCPXMJHSNVMWNM-UHFFFAOYSA-N Trihydroxyarsenite(Iii) Chemical compound O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 claims 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N Trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 206010046885 Vaginal cancer Diseases 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 229960003165 Vancomycin Drugs 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 208000009540 Villous Adenoma Diseases 0.000 claims 1
- 229960003048 Vinblastine Drugs 0.000 claims 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229960004528 Vincristine Drugs 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N XANTHOTOXIN Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims 1
- 206010048214 Xanthoma Diseases 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- 229960002184 abarelix Drugs 0.000 claims 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims 1
- 108010023617 abarelix Proteins 0.000 claims 1
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 229960005310 aldesleukin Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229960001445 alitretinoin Drugs 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- 229960000473 altretamine Drugs 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- 230000003444 anaesthetic Effects 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002469 antazoline Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliferant Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229960002594 arsenic trioxide Drugs 0.000 claims 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 201000005216 brain cancer Diseases 0.000 claims 1
- 201000003149 breast fibroadenoma Diseases 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229960002438 carfilzomib Drugs 0.000 claims 1
- 108010021331 carfilzomib Proteins 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 201000005217 chondroblastoma Diseases 0.000 claims 1
- 201000005262 chondroma Diseases 0.000 claims 1
- 201000009047 chordoma Diseases 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 229960000928 clofarabine Drugs 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229960003077 cycloserine Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 229960002923 denileukin diftitox Drugs 0.000 claims 1
- 108010017271 denileukin diftitox Proteins 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 108010063231 eculizumab Proteins 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000009051 embryonal carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000010934 exostosis Diseases 0.000 claims 1
- 201000001342 fallopian tube cancer Diseases 0.000 claims 1
- 230000001605 fetal Effects 0.000 claims 1
- 229960004884 fluconazole Drugs 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 230000002489 hematologic Effects 0.000 claims 1
- 201000002735 hepatocellular adenoma Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 102000006639 indoleamine 2,3-dioxygenase family Human genes 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase family Proteins 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 claims 1
- 229960001614 levamisole Drugs 0.000 claims 1
- 229960001120 levocabastine Drugs 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 229960002422 lomefloxacin Drugs 0.000 claims 1
- 229960002247 lomustine Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 201000000289 malignant teratoma Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 229960000901 mepacrine Drugs 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 229960002509 miconazole Drugs 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 229960004719 nandrolone Drugs 0.000 claims 1
- 229960005016 naphazoline Drugs 0.000 claims 1
- 235000010298 natamycin Nutrition 0.000 claims 1
- 239000004311 natamycin Substances 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 201000010133 oligodendroglioma Diseases 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 229940005931 ophthalmologic Fluoroquinolone antiinfectives Drugs 0.000 claims 1
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 108010044644 pegfilgrastim Proteins 0.000 claims 1
- 229960003349 pemetrexed disodium Drugs 0.000 claims 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 229960000952 pipobroman Drugs 0.000 claims 1
- 230000001855 preneoplastic Effects 0.000 claims 1
- 229960000624 procarbazine Drugs 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 201000010208 seminoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000001839 skull cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011096 spinal cancer Diseases 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229940041075 systemic Fluoroquinolone antibacterials Drugs 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 1
- 229940026752 topical Sulfonamides Drugs 0.000 claims 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 229960000497 trovafloxacin Drugs 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 229960001055 uracil mustard Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
- 150000003952 β-lactams Chemical class 0.000 claims 1
Claims (47)
- がん、ウイルス性疾患およびβグロビン症から選択される疾患の治療のための医薬であって、式:
環Aは、フェニルであり;
環Cは、シクロプロピル、シクロブチル、シクロヘキシル、アゼチジニル、またはピペリジニルであり;
R1は、ハロであり;
R3はそれぞれ独立して、ハロ、C1−6アルキル、C2−6アルケニル、C2−6アルキニル、C1−6ハロアルキル、C6−10アリール、C3−10シクロアルキル、5〜10員のヘテロアリール、4〜10員のヘテロシクロアルキル、C6−10アリール−C1−4アルキル−、C3−10シクロアルキル−C1−4アルキル−、(5〜10員ヘテロアリール)−C1−4アルキル−、(4〜10員ヘテロシクロアルキル)−C1−4アルキル−、CN、NO2、ORa2、SRa2、C(O)Rb2、C(O)NRc2Rd2、C(O)ORa2、OC(O)Rb2、OC(O)NRc2Rd2、NRc2Rd2、NRc2C(O)Rb2、NRc2C(O)ORa2、NRc2C(O)NRc2Rd2、NRc2S(O)Rb2、NRc2S(O)2Rb2、NRc2S(O)2NRc2Rd2、S(O)Rb2、S(O)NRc2Rd2、S(O)2Rb2、及びS(O)2NRc2Rd2から選択され、ここで前記C1−6アルキル、C2−6アルケニル、C2−6アルキニル、C6−10アリール、C3−10シクロアルキル、5〜10員のヘテロアリール、4〜10員のヘテロシクロアルキル、C6−10アリール−C1−4アルキル−、C3−10シクロアルキル−C1−4アルキル−、(5〜10員ヘテロアリール)−C1−4アルキル−、及び(4〜10員ヘテロシクロアルキル)−C1−4アルキル−はそれぞれ、ハロ、C1−4アルキル、C1−4ハロアルキル、C1−4シアノアルキル、CN、NO2、ORa2、SRa2、C(O)Rb2、C(O)NRc2Rd2、C(O)ORa2、OC(O)Rb2、OC(O)NRc2Rd2、NRc2Rd2、NRc2C(O)Rb2、NRc2C(O)ORa2、NRc2C(O)NRc2Rd2、NRc2S(O)Rb2、NRc2S(O)2Rb2、NRc2S(O)2NRc2Rd2、S(O)Rb2、S(O)NRc2Rd2、S(O)2Rb2、及びS(O)2NRc2Rd2から独立して選択される1、2、3、または4つの置換基で置換されていてもよく;
R4は、CN、C(O)NRc3Rd3、ORa3またはC(O)ORa3により置換されていてもよい、C1−4アルキルであり;
R5及びR6はそれぞれ、Hであり;
Rzは、H、C1−4アルキル、またはC6−10アリール−C1−4アルキル−であって、ここで前記C1−4アルキル、及びC6−10アリール−C1−4アルキル−はそれぞれ、ハロまたはORa4により置換されていてもよく;
Ra2、Rb2、Rc2、及びRd2は、それぞれ独立して、H、C1−6アルキル、C1−4ハロアルキル、C2−6アルケニル、C2−6アルキニル、C6−10アリール、C3−10シクロアルキル、5〜10員のヘテロアリール、4〜10員のヘテロシクロアルキル、C6−10アリール−C1−4アルキル−、C3−10シクロアルキル−C1−4アルキル−、(5〜10員ヘテロアリール)−C1−4アルキル−、及び(4〜10員ヘテロシクロアルキル)−C1−4アルキル−から選択され、ここで前記C1−6アルキル、C2−6アルケニル、C2−6アルキニル、C6−10アリール、C3−10シクロアルキル、5〜10員のヘテロアリール、4〜10員のヘテロシクロアルキル、C6−10アリール−C1−4アルキル−、C3−10シクロアルキル−C1−4アルキル−、(5〜10員ヘテロアリール)−C1−4アルキル−、及び(4〜10員ヘテロシクロアルキル)−C1−4アルキル−は、C1−4アルキル、C1−4ハロアルキル、C1−4シアノアルキル、ハロ、CN、ORa5、C(O)Rb5、C(O)NRc5Rd5、C(O)ORa5、NRc5Rd5、NRc5C(O)Rb5、S(O)2Rb5、及びS(O)2NRc5Rd5から独立して選択される1、2、3、4、もしくは5つの置換基で置換されていてもよく;
Ra4は、それぞれ独立して、H、C1−6アルキル、及びC1−4ハロアルキルから選択され;
Ra3、Rc3及びRd3は、それぞれ独立して、H、C1−6アルキル、及びC1−4ハロアルキルから選択され;
Ra5、Rb5、Rc5、及びRd5は、それぞれ独立して、H、C1−4アルキル、及びC1−4ハロアルキルから選択され;
nは、0、または1であり;
pは、0、または1であり;
qは、0、または1である]
で示される化合物またはその医薬的に許容される塩、および1つ以上の追加の治療薬を含む、医薬。 - 化合物またはその医薬的に許容される塩が、式:
- 化合物またはその医薬的に許容される塩が、式:
- qが0である、請求項1から3のいずれか一項に記載の医薬。
- qが1である、請求項1から3のいずれか一項に記載の医薬。
- nが0である、請求項1から5のいずれか一項に記載の医薬。
- nが1である、請求項1から5のいずれか一項に記載の医薬。
- R1がFである、請求項1から7のいずれか一項に記載の医薬。
- 環Cが、アゼチジニルまたはピペリジニルである、請求項1から8のいずれか一項に記載の医薬。
- 環Cが、アゼチジニルである、請求項1から9のいずれか一項に記載の医薬。
- 環Cが、ピペリジニルである、請求項1から9のいずれか一項に記載の医薬。
- R4が、CN、C(O)NRc3Rd3またはC(O)ORa3で置換されていてもよいC1−4アルキルである、請求項1から11のいずれか一項に記載の医薬。
- R4が、−CH2−CN、−CH2−C(=O)OH、−CH2−C(=O)NH(CH3)、−CH2−C(=O)N(CH3)2、もしくは−CH2CH2OHである、請求項1から11のいずれか一項に記載の医薬。
- R3がそれぞれ独立して、C1−6アルキル、C6−10アリール、5〜10員のヘテロアリール、C3−10シクロアルキル、4〜10員のヘテロシクロアルキル、C(O)Rb2、C(O)NRc2Rd2、C(O)ORa2、S(O)2Rb2、及びS(O)2NRc2Rd2から選択され、ここで前記C1−6アルキル、C6−10アリール、5〜10員のヘテロアリール、C3−10シクロアルキル、及び4〜10員のヘテロシクロアルキルはそれぞれ、ハロ、C1−4アルキル、C1−4ハロアルキル、C1−4シアノアルキル、CN、NO2、ORa2、SRa2、C(O)Rb2、C(O)NRc2Rd2、C(O)ORa2、OC(O)Rb2、OC(O)NRc2Rd2、NRc2Rd2、NRc2C(O)Rb2、NRc2C(O)ORa2、NRc2C(O)NRc2Rd2、NRc2S(O)Rb2、NRc2S(O)2Rb2、NRc2S(O)2NRc2Rd2、S(O)Rb2、S(O)NRc2Rd2、S(O)2Rb2、及びS(O)2NRc2Rd2から独立して選択される1、2、3、もしくは4つの置換基で置換されていてもよい、請求項1から13のいずれか一項に記載の医薬。
- R3がそれぞれ独立して、C1−6アルキル、C6−10アリール、5〜10員のヘテロアリール、C(O)Rb2、C(O)NRc2Rd2、C(O)ORa2、S(O)2Rb2、及びS(O)2NRc2Rd2から選択され、ここで前記C1−6アルキル、C6−10アリール、及び5〜10員のヘテロアリールはそれぞれ、ハロ、C1−4アルキル、C1−4ハロアルキル、C1−4シアノアルキル、CN、NO2、ORa2、SRa2、C(O)Rb2、C(O)NRc2Rd2、C(O)ORa2、OC(O)Rb2、OC(O)NRc2Rd2、NRc2Rd2、NRc2C(O)Rb2、NRc2C(O)ORa2、NRc2C(O)NRc2Rd2、NRc2S(O)Rb2、NRc2S(O)2Rb2、NRc2S(O)2NRc2Rd2、S(O)Rb2、S(O)NRc2Rd2、S(O)2Rb2、及びS(O)2NRc2Rd2から独立して選択される1、2、3、もしくは4つの置換基で置換されていてもよい、請求項1から13のいずれか一項に記載の医薬。
- R3がそれぞれ独立して、C1−6アルキル、C6−10アリール、5〜10員のヘテロアリール、C(O)Rb2、C(O)NRc2Rd2、C(O)ORa2、及びS(O)2Rb2から選択され、ここで前記C1−6アルキル、C6−10アリール、及び5〜10員のヘテロアリールはそれぞれ、ハロ、C1−4アルキル、C1−4ハロアルキル、C1−4シアノアルキル、CN、NO2、ORa2、SRa2、C(O)Rb2、C(O)NRc2Rd2、C(O)ORa2、OC(O)Rb2、OC(O)NRc2Rd2、NRc2Rd2、NRc2C(O)Rb2、NRc2C(O)ORa2、NRc2C(O)NRc2Rd2、NRc2S(O)Rb2、NRc2S(O)2Rb2、NRc2S(O)2NRc2Rd2、S(O)Rb2、S(O)NRc2Rd2、S(O)2Rb2、及びS(O)2NRc2Rd2から独立して選択される1、2、3、または4つの置換基で置換されていてもよい、請求項1から13のいずれか一項に記載の医薬。
- RzがC1−4アルキルである、請求項1、2、及び4から16のいずれか一項に記載の医薬。
- Rzが、メトキシで置換されたC1−4アルキルである、請求項1、2、及び4から16のいずれか一項に記載の医薬。
- Rzが、フルオロで置換されたC6−10アリール−C1−4アルキル−である、請求項1、2、及び4から16のいずれか一項に記載の医薬。
- Rzが、H、メチル、メトキシメチル、もしくは4−フルオロフェニルメチルである、請求項1、2、及び4から16のいずれか一項に記載の医薬。
- RzがHである、請求項1、2、及び4から16のいずれか一項に記載の医薬。
- pが0である、請求項1から21のいずれか一項に記載の医薬。
- pが1である、請求項1から21のいずれか一項に記載の医薬。
- 化合物またはその医薬的に許容される塩が、請求項1に記載の式に示される二置換のシクロプロピル基に関して、トランス配置を有する、請求項1から23のいずれか一項に記載の医薬。
- 化合物が、
(1−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}シクロブチル)アセトニトリル;
(1−メチル−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−3−イル)アセトニトリル;
(3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−3−イル)アセトニトリル;
(1−ベンジル−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−3−イル)アセトニトリル;
3−(3−(シアノメチル)−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−1−イル)プロパン酸;
(1−アセチル−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−3−イル)アセトニトリル;
(1−ベンゾイル−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−3−イル)アセトニトリル;
メチル3−(シアノメチル)−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−1−カルボキシレート;
(1−(メチルスルホニル)−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−3−イル)アセトニトリル;
2−(3−(シアノメチル)−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−1−イル)ニコチノニトリル;
3−シアノ−4−(3−(シアノメチル)−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−1−イル)安息香酸;
2−(3−(シアノメチル)−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−1−イル)ベンゾニトリル;
4−(3−(シアノメチル)−3−{4−[(trans−2−フェニルシクロプロピル)アミノ]ピペリジン−1−イル}アゼチジン−1−イル)ベンゾニトリル;
[1−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)シクロブチル]アセトニトリル
(1’−(エチルスルホニル)−3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}−1,3’−ビアゼチジン−3’−イル)アセトニトリル;
[4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−4−イル]アセトニトリル;
[1−メチル−4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−4−イル]アセトニトリル;
[1−アセチル−4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−4−イル]アセトニトリル
[1−(4−フルオロベンゾイル)−4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−4−イル]アセトニトリル;
[1−(メチルスルホニル)−4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−4−イル]アセトニトリル;
[4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)−1−(フェニルスルホニル)ピペリジン−4−イル]アセトニトリル;
エチル4−(シアノメチル)−4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−1−カルボキシレート
4−(シアノメチル)−N,N−ジメチル−4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−1−カルボキサミド;
4−(シアノメチル)−N−イソプロピル−4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−1−カルボキサミド;
4−(シアノメチル)−N−(4−フルオロフェニル)−4−(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}アゼチジン−1−イル)ピペリジン−1−カルボキサミド;
(3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}−1,3’−ビアゼチジン−3’−イル)アセトニトリル;
4−(3’−(シアノメチル)−3−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}−1,3’−ビアゼチジン−1’−イル)−2,5−ジフルオロ−N−[(1S)−2,2,2−トリフルオロ−1−メチルエチル]ベンズアミド;
[1−(エチルスルホニル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)シクロブチル]アセトニトリル;
[3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
2−[3−(シアノメチル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−1−イル]ニコチノニトリル;
4−[3−(シアノメチル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−1−イル]−2,5−ジフルオロ−N−イソプロピルベンズアミド;
{3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)−1−[3−(トリフルオロメチル)ピリジン−2−イル]アゼチジン−3−イル}アセトニトリル;
{3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)−1−[5−(トリフルオロメチル)ピリジン−2−イル]アゼチジン−3−イル}アセトニトリル;
2−クロロ−6−[3−(シアノメチル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−1−イル]ベンゾニトリル;
2−[3−(シアノメチル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−1−イル]ベンゾニトリル;
4−[3−(シアノメチル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−1−イル]ベンゾニトリル;
メチル3−(シアノメチル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−1−カルボキシレート;
3−(シアノメチル)−N−(2,4−ジフルオロフェニル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−1−カルボキサミド;
N−(3−クロロ−2−フルオロフェニル)−3−(シアノメチル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−1−カルボキサミド;
[1−(3,5−ジフルオロベンゾイル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−ベンゾイル−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(2−フルオロベンゾイル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(3−フルオロベンゾイル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(4−フルオロベンゾイル)−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−メチル−3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(trans−2−フェニルシクロプロピル)アミノ]メチル}ピペリジン−1−イル)アゼチジン−3−イル]酢酸;
N−メチル−2−(3−(4−((trans−2−フェニルシクロプロピルアミノ)メチル)ピペリジン−1−イル)アゼチジン−3−イル)アセタミド;及び
N,N−ジメチル−2−(3−(4−((trans−2−フェニルシクロプロピルアミノ)メチル)ピペリジン−1−イル)アゼチジン−3−イル)アセタミド
から選択されるかまたは前記化合物のいずれかの医薬的に許容される塩である、請求項1に記載の医薬。 - 化合物が、
{1−[4−(4−フルオロベンジル)−4−({[(1R,2S)−2−フェニルシクロプロピル]アミノ}メチル)ピペリジン−1−イル]シクロブチル}酢酸;
{1−[4−(メトキシメチル)−4−({[(1R,2S)−2−フェニルシクロプロピル]アミノ}メチル)ピペリジン−1−イル]シクロブチル}酢酸;
{1−[4−メチル−4−({[(1R,2S)−2−フェニルシクロプロピル]アミノ}メチル)ピペリジン−1−イル]シクロブチル}酢酸;
N,N−ジメチル−2−{1−[4−メチル−4−({[(1R,2S)−2−フェニルシクロプロピル]アミノ}メチル)ピペリジン−1−イル]シクロブチル}アセタミド;
N−メチル−2−{1−[4−メチル−4−({[(1R,2S)−2−フェニルシクロプロピル]アミノ}メチル)ピペリジン−1−イル]シクロブチル}アセタミド;
[1−(メチルスルホニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−メチル−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1S,2R)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(エチルスルホニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
3−(シアノメチル)−N,N−ジメチル−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミド;
3−(シアノメチル)−N−メチル−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミド;
3−(シアノメチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミド;
[1−メチル−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]酢酸;
[1−エチル−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]酢酸;
N,N−ジメチル−2−[1−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)シクロブチル]アセタミド;
N−メチル−2−[1−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)シクロブチル]アセタミド;
2−[1−(エチルスルホニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]−N,N−ジメチルアセタミド;及び
2−[1−(エチルスルホニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]−N−メチルアセタミド
から選択されるかまたは前記化合物のいずれか1つの医薬的に許容される塩である、請求項1に記載の医薬。 - 化合物が、
[1−(1−メチル−1H−ピラゾール−4−イル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(2−ヒドロキシエチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(3−ヒドロキシシクロブチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル}アセトニトリル;
[1−(cis−4−ヒドロキシシクロヘキシル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(イソチアゾール−5−イルカルボニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(モルホリン−4−イルカルボニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−(trans−4−ヒドロキシシクロヘキシル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(1−ヒドロキシシクロペンチル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(1−ヒドロキシシクロプロピル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(1−メチル−1H−ピラゾール−4−イル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(1−メチル−1H−ピラゾール−4−イル)スルホニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(1−メチル−1H−ピラゾール−5−イル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(3−ヒドロキシアゼチジン−1−イル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(4−ヒドロキシピペリジン−1−イル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(4−メトキシピペリジン−1−イル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(cis−4−ヒドロキシシクロヘキシル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[1−[(trans−4−ヒドロキシシクロヘキシル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−(4−フルオロフェニル)シクロプロピル]アミノ}ピペリジン−1−イル)−1−(4−ヒドロキシシクロヘキシル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−(4−フルオロフェニル)シクロプロピル]アミノ}ピペリジン−1−イル)−1−(メチルスルホニル)−アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(1,3−チアゾール−5−イルカルボニル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(1H−ピラゾール−4−イルカルボニル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(ピラジン−2−イルカルボニル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(テトラヒドロ−2H−ピラン−4−イル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(テトラヒドロフラン−3−イル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(テトラヒドロフラン−3−イルカルボニル)アゼチジン−3−イル]アセトニトリル;
{1−[4−({[(1R,2S)−2−フェニルシクロプロピル]アミノ}メチル)ピペリジン−1−イル]シクロブチル}酢酸;
2−(3−(4−(((1R,2S)−2−フェニルシクロプロピル)アミノ)ピペリジン−1−イル)−1−(テトラヒドロフラン−2−カルボニル)アゼチジン−3−イル)アセトニトリル;
2−(3−(シアノメチル)−3−(4−(((1R,2S)−2−フェニルシクロプロピル)アミノ)ピペリジン−1−イル)アゼチジン−1−イル)−N,N−ジメチルアセタミド;
2−[1−(エチルスルホニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]エタノール;
2−[1−(メチルスルホニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]エタノール;
2−[3−(シアノメチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−イル]アセタミド;
2−[3−(シアノメチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−イル]−N−メチルアセタミド
3−(シアノメチル)−3−(4−{[(1R,2S)−2−(4−フルオロフェニル)シクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミド;
3−[2−(ジメチルアミノ)−2−オキソエチル]−N,N−ジメチル−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−カルボキサミド;
メチル3−[2−(ジメチルアミノ)−2−オキソエチル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−カルボキシレート;
メチル3−[2−(メチルアミノ)−2−オキソエチル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−カルボキシレート;
N,N−ジメチル−2−(1−(メチルスルホニル)−3−(4−(((1R,2S)−2−フェニルシクロプロピル)アミノ)ピペリジン−1−イル)アゼチジン−3−イル)アセタミド;
N,N−ジメチル−3−[2−(メチルアミノ)−2−オキソエチル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−カルボキサミド;
N−メチル−2−[1−(メチルスルホニル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセタミド;
テトラヒドロフラン−3−イル3−(シアノメチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−カルボキシレート;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(1H−ピラゾール−5−イルカルボニル)アゼチジン−3−イル]アセトニトリル;
{3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−[(3R)−テトラヒドロフラン−3−イルカルボニル]アゼチジン−3−イル}アセトニトリル;
{3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−[(3S)−テトラヒドロフラン−3−イルカルボニル]アゼチジン−3−イル}アセトニトリル;
{3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−[(2S)−テトラヒドロフラン−2−イルカルボニル]アゼチジン−3−イル}アセトニトリル;
{3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−[(2R)−テトラヒドロフラン−2−イルカルボニル]アゼチジン−3−イル}アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(ピリジン−2−イルアセチル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(1,3−チアゾール−4−イルカルボニル)アゼチジン−3−イル]アセトニトリル;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(1,3−チアゾール−2−イルカルボニル)アゼチジン−3−イル]アセトニトリル;
N,N−ジメチル−2−[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(テトラヒドロ−2H−ピラン−4−イル)アゼチジン−3−イル]アセタミド;
N−メチル−2−[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(テトラヒドロ−2H−ピラン−4−イル)アゼチジン−3−イル]アセタミド;
2−[1−(シクロプロピルメチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]−N,N−ジメチルアセタミド;
2−[1−(シクロプロピルメチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]−N−メチルアセタミド;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(ピリミジン−2−イルメチル)アゼチジン−3−イル]酢酸;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(ピリミジン−5−イルメチル)アゼチジン−3−イル]酢酸;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(1,3−チアゾール−4−イルメチル)アゼチジン−3−イル]酢酸;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(1,3−チアゾール−5−イルメチル)アゼチジン−3−イル]酢酸;
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(1,3−チアゾール−2−イルメチル)アゼチジン−3−イル]酢酸;及び
[3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)−1−(3,3,3−トリフルオロプロピル)アゼチジン−3−イル]酢酸
から選択されるかまたは前記化合物のいずれかの医薬的に許容される塩である、請求項1に記載の医薬。 - 化合物またはその医薬的に許容される塩が、3−(シアノメチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミドまたはその医薬的に許容される塩である、請求項1に記載の医薬。
- 化合物が、3−(シアノメチル)−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミドである、請求項1に記載の医薬。
- 化合物またはその医薬的に許容される塩が、[1−[(1−メチル−1H−ピラゾール−4−イル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリルまたはその医薬的に許容される塩である、請求項1に記載の医薬。
- 化合物が、[1−[(1−メチル−1H−ピラゾール−4−イル)カルボニル]−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−3−イル]アセトニトリルである、請求項1に記載の医薬。
- 化合物またはその医薬的に許容される塩が、3−(シアノメチル)−N,N−ジメチル−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミドまたはその医薬的に許容される塩である、請求項1に記載の医薬。
- 化合物が、3−(シアノメチル)−N,N−ジメチル−3−(4−{[(1R,2S)−2−フェニルシクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミドである、請求項1に記載の医薬。
- 化合物またはその医薬的に許容される塩が、3−(シアノメチル)−3−(4−{[(1R,2S)−2−(4−フルオロフェニル)シクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミドまたはその医薬的に許容される塩である、請求項1に記載の医薬。
- 化合物が、3−(シアノメチル)−3−(4−{[(1R,2S)−2−(4−フルオロフェニル)シクロプロピル]アミノ}ピペリジン−1−イル)アゼチジン−1−スルホンアミドである、請求項1に記載の医薬。
- 疾患が、がんである、請求項1から35のいずれか一項に記載の医薬。
- 1つ以上の追加の治療薬が、化学療法剤、抗増殖剤、アバレリクス、アルデスロイキン、アレムツズマブ、アリトレチノイン、アロプリノール、アルトレタミン、アナストロゾール、三酸化ヒ素、アスパラギナーゼ、アザシチジン、ベンダムスチン、ベバシズマブ、ベキサロテン、ブレオマイシン、ボルテゾムビ(bortezombi)、ボルテゾミブ、ブスルファン静注、ブスルファン経口、カルステロン、カペシタビン、カルボプラチン、カルムスチン、セツキシマブ、クロラムブシル、シスプラチン、クラドリビン、クロファラビン、シクロホスファミド、シタラビン、デカルバジン、ダクチノマイシン、ダルテパリンナトリウム、ダサチニブ、ダウノルビシン、デシタビン、デニロイキン、デニロイキンジフチトクス、デクスラゾキサン、ドセタキセル、ドキソルビシン、プロピオン酸ドロモスタノロン、エクリズマブ、エピルビシン、エルロチニブ、エストラムスチン、リン酸エトポシド、エトポシド、エキセメスタン、クエン酸フェンタニル、フィルグラスチム、フロクスウリジン、フルダラビン、フルオロウラシル、フルベストラント、ゲフィチニブ、ゲムシタビン、ゲムツズマブオゾガマイシン、酢酸ゴセレリン、酢酸ヒストレリン、イブリツモマブチウキセタン、イダルビシン、イホスファミド、メシル酸イマチニブ、インターフェロンアルファ2a、イリノテカン、トシル酸ラパチニブ、レナリドマイド、レトロゾール、ロイコボリン、酢酸リュープロリド、レバミソール、ロムスチン、メクロレタミン、酢酸メゲストロール、メルファラン、メルカプトプリン、メトトレキサート、メトキサレン、マイトマイシンC、ミトタン、ミトキサントロン、フェンプロピオン酸ナンドロロン、ネララビン、ノフェツモマブ、オキサリプラチン、パクリタキセル、パミドロネート、パニツムマブ、パノビノスタット、ペグアスパルガーゼ、ペグフィルグラスチム、ペメトレキセド二ナトリウム、ペントスタチン、ピポブロマン、プリカマイシン、プロカルバジン、キナクリン、ラスブリカーゼ、リツキシマブ、ルクソリチニブ、ソラフェニブ、ストレプトゾシン、スニチニブ、スニチニブマレエート(sunitinib maleate)、タモキシフェン、テモゾロミド、テニポシド、テストラクトン、サリドマイド、チオグアニン、チオテパ、トポテカン、トレミフェン、トシツモマブ、トラスツズマブ、トレチノイン、ウラシルマスタード、バルルビシン、ビンブラスチン、ビンクリスチン、ビノレルビン、ボリノスタット、ゾレドロネート、JAKキナーゼ阻害剤、Pimキナーゼ阻害剤、PI3キナーゼ阻害剤、PI3K−デルタ選択的及び広域PI3K阻害剤、MEK阻害剤、サイクリン依存性キナーゼ阻害剤、b−RAF阻害剤、mTOR阻害剤、プロテアソーム阻害剤、ボルテゾミブ、カーフィルゾミブ、HDAC阻害剤、パノビノスタット、ボリノスタット、DNAメチルトランスフェラーゼ阻害剤、デキサメタゾン、ブロモ及び特異的末端ファミリーメンバー阻害剤、及びインドールアミン2,3−ジオキシゲナーゼ阻害剤からなる群から選択される、請求項36に記載の医薬。
- がんが、血液がん、リンパ腫、白血病、急性リンパ性白血病(ALL)、急性骨髄性白血病(AML)、急性前骨髄球性白血病(APL)、慢性リンパ球性白血病(CLL)、慢性骨髄性白血病(CML)、びまん性大細胞型B細胞リンパ腫(DLBCL)、マントル細胞リンパ腫、非ホジキンリンパ腫、再発性または難治性NHL、反復濾胞性NHL、ホジキンリンパ腫、骨髄増殖性疾患、原発性骨髄線維症(PMF)、真性赤血球増加症(PV)、本態性血小板血症(ET)、骨髄異形成症候群(MDS)、多発性骨髄腫、非上皮性悪性腫瘍、軟骨肉腫、ユーイング肉腫、骨肉腫、横紋筋肉腫、血管肉腫、線維肉腫、脂肪肉腫、粘液腫、横紋筋腫、線維腫、脂肪腫、過誤腫、奇形腫、肺がん、非小細胞肺がん(NSCLC)、気管支原性肺がん、扁平細胞がん、未分化小細胞がん、未分化大細胞がん、腺がん、肺胞(細気管支)がん、気管支腺腫、軟骨性過誤腫、中皮腫、消化管がん、食道がん、扁平上皮がん、腺がん、平滑筋肉腫、リンパ腫、胃がん、上皮性悪性腫瘍、リンパ腫、平滑筋肉腫、膵臓がん、導管腺がん、インスリノーマ、グルカゴノーマ、ガストリノーマ、カルチノイド腫瘍、ビポーマ、小腸がん、腺がん、リンパ腫、カルチノイド腫瘍、カポジ肉腫、平滑筋腫、血管腫、脂肪腫、神経線維腫、線維腫、大腸がん、腺がん、管状腺腫、絨毛腺腫、過誤腫、平滑筋腫、結腸直腸がん、泌尿生殖器系がん、腎臓がん、腺がん、ウィルムス腫瘍[腎芽腫]、膀胱及び尿道がん、扁平上皮がん、移行上皮がん、腺がん、前立腺がん、腺がん、非上皮性悪性腫瘍、精巣がん、セミノーマ、奇形腫、胚性がん腫、奇形がん腫、絨毛がん、非上皮性悪性腫瘍、間質細胞がん、線維腫、線維腺腫、腺腫様腫瘍、脂肪腫、肝臓がん、肝細胞腫、肝細胞がん、胆管細胞がん、肝芽腫、血管肉腫、肝細胞腺腫、血管腫、骨がん、骨原性肉腫、骨肉腫、線維肉腫、悪性線維性組織球腫、軟骨肉腫、ユーイング肉腫、悪性リンパ腫、細網肉腫、多発性骨髄腫、悪性巨細胞腫脊索腫、オステオクロンフローマ、骨軟骨性外骨症、良性軟骨腫、軟骨芽細胞腫、軟骨粘液線維腫、類骨腫、巨細胞腫、神経系のがん、頭蓋のがん、骨腫、血管腫、肉芽腫、黄色腫、変形性骨炎、髄膜がん、髄膜腫、髄膜肉腫、神経膠腫症、脳がん、星状細胞腫、髄芽腫、神経膠腫、上衣腫、胚細胞腫、松果体腫、多形性膠芽腫、乏突起膠腫、神経鞘腫、網膜芽細胞腫、先天性腫瘍、脊髄がん、神経繊維腫、髄膜腫、神経膠腫、非上皮性悪性腫瘍、神経芽細胞腫、レルミット・デュクロ病、婦人科がん、子宮がん、子宮内膜がん、子宮頸部のがん、子宮頸がん、前腫瘍の子宮頸部異形成、卵巣のがん、卵巣がん、漿液性嚢胞腺がん、粘液性嚢胞腺癌、未分類の上皮性悪性腫瘍、包膜莢膜細胞腫、セルトリ・ライディッヒ細胞腫、未分化胚細胞腫、悪性奇形腫、外陰がん、扁平上皮がん、上皮内がん、腺がん、線維肉腫、黒色腫、膣がん、明細胞癌、扁平上皮がん、ブドウ状横紋筋肉腫、胎児性横紋筋肉腫、卵管がん、上皮性悪性腫瘍、皮膚がん、黒色腫、基底細胞がん、扁平上皮がん、カポジ肉腫、ほくろの異形成母斑、脂肪腫、血管腫、皮膚線維腫、ケロイド、乳がん、前立腺がん、頭頸部がん、喉頭部がん、口腔がん、甲状腺がん、及び甲状腺乳頭がんからなる群から選択される、請求項36に記載の医薬。
- がんが、骨髄異形成症候群である、請求項36に記載の医薬。
- がんが、急性骨髄性白血病である、請求項36に記載の医薬。
- がんが、未分化小細胞がんである、請求項36に記載の医薬。
- がんが、ユーイング肉腫である、請求項36に記載の医薬。
- がんが、原発性骨髄線維症である、請求項36に記載の医薬。
- 疾患が、ウイルス性疾患である、請求項1から35のいずれか一項に記載の医薬。
- 1つ以上の追加の治療薬が、抗生物質製剤、抗ウイルス薬、抗真菌薬、麻酔薬、抗炎症薬、ステロイド系及び非ステロイド系抗炎症薬、抗アレルギー薬、アミノグリコシド類、アミカシン、ゲンタマイシン、トブラマイシン、ストレプトマイシン、ネチルマイシン、カナマイシン、フルオロキノロン類、シプロフロキサシン、ノルフロキサシン、オフロキサシン、トロバフロキサシン、ロメフロキサシン、レボフロキサシン、エノキサシン、ナフチリジン、スルホンアミド類、ポリミキシン、クロラムフェニコール、ネオマイシン、パラモマイシン、コリスチメタート、バシトラシン、バンコマイシン、テトラサイクリン類、リファンピン、リファンピン誘導体(「リファンピン類」)、サイクロセリン、ベータラクタム類、セファロスポリン類、アンホテリシン類、フルコナゾール、フルシトシン、ナタマイシン、ミコナゾール、ケトコナゾール、コルチコステロイド類、ジクロフェナク、フルルビプロフェン、ケトロラク、スプロフェン、クロモリン、ロドキサミド、レボカバスチン、ナファゾリン、アンタゾリン、フェニラミン、及びアザライド系抗生物質からなる群から選択される、請求項44に記載の医薬。
- ウイルス性疾患が、単純ヘルペスウイルス(HSV)、水痘帯状ヘルペスウイルス(VZV)、ヒトサイトメガロウイルス、B型肝炎ウイルス(HBV)、及びアデノウイルスからなる群から選択される、請求項44に記載の医薬。
- 化合物またはその医薬的に許容される塩と1つ以上の追加の治療薬とが同時または順次に投与される、請求項1から46のいずれか一項に記載の医薬。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461939458P | 2014-02-13 | 2014-02-13 | |
US61/939,458 | 2014-02-13 | ||
US201462061258P | 2014-10-08 | 2014-10-08 | |
US62/061,258 | 2014-10-08 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016551815A Division JP6602779B2 (ja) | 2014-02-13 | 2015-02-12 | Lsd1阻害剤としてのシクロプロピルアミン類 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020174661A Division JP2021011496A (ja) | 2014-02-13 | 2020-10-16 | Lsd1阻害剤としてのシクロプロピルアミン類 |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2020023529A JP2020023529A (ja) | 2020-02-13 |
JP2020023529A6 JP2020023529A6 (ja) | 2020-04-16 |
JP2020023529A5 true JP2020023529A5 (ja) | 2020-05-21 |
JP6781815B2 JP6781815B2 (ja) | 2020-11-04 |
Family
ID=52595463
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016551815A Active JP6602779B2 (ja) | 2014-02-13 | 2015-02-12 | Lsd1阻害剤としてのシクロプロピルアミン類 |
JP2019186168A Active JP6781815B2 (ja) | 2014-02-13 | 2019-10-09 | Lsd1阻害剤としてのシクロプロピルアミン類 |
JP2020174661A Pending JP2021011496A (ja) | 2014-02-13 | 2020-10-16 | Lsd1阻害剤としてのシクロプロピルアミン類 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016551815A Active JP6602779B2 (ja) | 2014-02-13 | 2015-02-12 | Lsd1阻害剤としてのシクロプロピルアミン類 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020174661A Pending JP2021011496A (ja) | 2014-02-13 | 2020-10-16 | Lsd1阻害剤としてのシクロプロピルアミン類 |
Country Status (33)
Country | Link |
---|---|
US (4) | US9493450B2 (ja) |
EP (2) | EP3626714A1 (ja) |
JP (3) | JP6602779B2 (ja) |
KR (1) | KR102352408B1 (ja) |
CN (1) | CN106488915B (ja) |
AU (2) | AU2015217119C1 (ja) |
BR (1) | BR112016018555B1 (ja) |
CA (1) | CA2939081C (ja) |
CL (1) | CL2016002021A1 (ja) |
CR (2) | CR20200362A (ja) |
CY (1) | CY1122314T1 (ja) |
DK (1) | DK3105226T3 (ja) |
EA (1) | EA201691594A1 (ja) |
EC (1) | ECSP16073171A (ja) |
ES (1) | ES2750956T3 (ja) |
HR (1) | HRP20192033T1 (ja) |
HU (1) | HUE045725T2 (ja) |
IL (2) | IL246950B (ja) |
LT (1) | LT3105226T (ja) |
ME (1) | ME03580B (ja) |
MX (2) | MX2016010390A (ja) |
MY (1) | MY196877A (ja) |
NZ (1) | NZ723203A (ja) |
PE (1) | PE20161384A1 (ja) |
PH (1) | PH12016501546A1 (ja) |
PL (1) | PL3105226T3 (ja) |
PT (1) | PT3105226T (ja) |
RS (1) | RS59534B1 (ja) |
SG (2) | SG10201806846RA (ja) |
SI (1) | SI3105226T1 (ja) |
TW (2) | TWI720451B (ja) |
UA (1) | UA122389C2 (ja) |
WO (1) | WO2015123424A1 (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2901711T3 (es) | 2014-02-13 | 2022-03-23 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
AU2016275702A1 (en) | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
EP3397616B1 (en) | 2015-12-29 | 2020-06-10 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
CN109195593A (zh) | 2016-03-15 | 2019-01-11 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
CN107200706A (zh) * | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
CN107459476B (zh) * | 2016-06-03 | 2022-06-24 | 中国科学院上海药物研究所 | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 |
EP3535414A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
CN110914265B (zh) | 2017-05-15 | 2022-12-23 | 密歇根大学董事会 | 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物 |
SG11202000077RA (en) | 2017-08-03 | 2020-02-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
WO2019222069A1 (en) | 2018-05-15 | 2019-11-21 | The Regents Of The University Of Michigan | Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
AU2020242302A1 (en) | 2019-03-20 | 2021-09-16 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
WO2020188089A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
EP3994280A1 (en) | 2019-07-05 | 2022-05-11 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
MX2023011779A (es) | 2021-04-08 | 2023-11-22 | Oryzon Genomics Sa | Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides. |
WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (316)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7013068A (ja) | 1969-09-17 | 1971-03-19 | ||
US4537889A (en) | 1982-12-27 | 1985-08-27 | Eli Lilly And Company | Inotropic agents |
US4614810A (en) | 1984-09-24 | 1986-09-30 | Pennwalt Corporation | 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof |
US4625040A (en) | 1984-09-24 | 1986-11-25 | Pennwalt Corporation | N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives |
FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
JPH032778Y2 (ja) | 1986-12-15 | 1991-01-24 | ||
AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
JP2844351B2 (ja) | 1989-07-13 | 1999-01-06 | 株式会社科薬 | 安定なポリミキシン系抗生物質水性溶液 |
IL96432A0 (en) | 1989-11-30 | 1991-08-16 | Schering Ag | Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives |
FR2662163A1 (fr) | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
DK0649425T3 (da) | 1992-06-17 | 1999-09-27 | Upjohn Co | Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester |
JP2923139B2 (ja) | 1992-10-05 | 1999-07-26 | 三井化学株式会社 | 製 剤 |
DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
EP1050535A4 (en) | 1997-11-11 | 2001-04-25 | Ono Pharmaceutical Co | CONDENSED PYRAZINE DERIVATIVES |
JP2000319277A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
JP2000319278A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
JP4032566B2 (ja) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | 発光素子 |
JP4041624B2 (ja) | 1999-07-21 | 2008-01-30 | 三井化学株式会社 | 有機電界発光素子 |
JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
RS50303B (sr) | 1999-09-28 | 2009-09-08 | Panacea Biotec Limited, | Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem |
SE9903611D0 (sv) | 1999-10-06 | 1999-10-06 | Astra Ab | Novel compounds III |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
JP4409680B2 (ja) | 1999-10-18 | 2010-02-03 | 株式会社ヤクルト本社 | 三環性縮合イミダゾール誘導体 |
AU2001252609A1 (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd. | Imidazopyridine derivatives |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
US6589952B2 (en) | 2000-07-14 | 2003-07-08 | Bristol-Myers Squibb Pharma Company | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders |
DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
WO2002034748A1 (en) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Imidazopyridine derivatives |
JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
WO2002038568A1 (en) | 2000-11-10 | 2002-05-16 | Merck Sharp & Dohme Limited | Imidazo-triazine derivatives as ligands for gaba receptors |
WO2002048146A2 (de) | 2000-12-13 | 2002-06-20 | Basf Aktiengesellschaft | Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
WO2002072549A1 (en) | 2001-03-12 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Edg受容体に関連する症状の処置方法 |
AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
EP1576150A4 (en) | 2002-10-16 | 2006-05-03 | Univ Texas | METHODS AND COMPOSITIONS FOR INCREASING THE EFFICACY OF ACTIVE SUBSTANCES FROM A BIOLOGICAL VIEWPOINT |
AU2003301226A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corp | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
CN101928284A (zh) | 2003-03-14 | 2010-12-29 | 小野药品工业株式会社 | 含氮杂环衍生物以及包含所述化合物作为活性成分的药物 |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
DK1615647T3 (da) | 2003-04-11 | 2010-04-06 | High Point Pharmaceuticals Llc | Farmaceutisk anvendelse af kondenserede 1,2,4-triazoler |
JP4616831B2 (ja) | 2003-04-24 | 2011-01-19 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
EP1663193B1 (en) | 2003-09-12 | 2012-04-04 | Merck Serono SA | Sulfonamide derivatives for the treatment of diabetes |
JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
DE602004008098T8 (de) | 2003-10-10 | 2008-04-17 | Pfizer Products Inc., Groton | Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren |
US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
US7714009B2 (en) | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
US20080249154A1 (en) | 2003-12-26 | 2008-10-09 | Ono Pharmaceutical Co., Ltd. | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates |
WO2005077948A1 (ja) | 2004-02-16 | 2005-08-25 | Daiichi Pharmaceutical Co., Ltd. | 抗真菌作用複素環化合物 |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
BRPI0510319A (pt) * | 2004-04-26 | 2007-10-16 | Pfizer | inibidores da enzima integrase de hiv |
ES2370729T3 (es) | 2004-05-11 | 2011-12-22 | Egalet Ltd. | Forma farmacéutica hinchable que comprende goma gellan. |
TW200612918A (en) | 2004-07-29 | 2006-05-01 | Threshold Pharmaceuticals Inc | Lonidamine analogs |
JP2008509985A (ja) | 2004-08-18 | 2008-04-03 | ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー | 炎症治療用の新規トリアゾロピリジン化合物 |
JP2008511669A (ja) | 2004-09-02 | 2008-04-17 | スミスクライン ビーチャム コーポレーション | 化合物 |
WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
US20090042820A1 (en) | 2004-11-22 | 2009-02-12 | Threshold Pharmaceuticals, Inc. | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof |
WO2006058752A1 (en) | 2004-12-01 | 2006-06-08 | Laboratoires Serono S.A. | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
US20070293456A9 (en) | 2004-12-30 | 2007-12-20 | Anthony Hayford | Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds |
US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
AU2006217534B8 (en) | 2005-02-22 | 2011-12-08 | Pfizer Inc. | Oxyindole derivatives as 5HT4 receptor agonists |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
JP2008536950A (ja) | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのcb1拮抗薬 |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
CA2611391A1 (en) | 2005-06-09 | 2006-12-14 | Oncalis Ag | Angiogenesis inhibitors |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
TW200726765A (en) | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
JP2009507843A (ja) | 2005-09-09 | 2009-02-26 | シェーリング コーポレイション | アザ縮合サイクリン依存性キナーゼ阻害剤 |
AR056785A1 (es) | 2005-11-10 | 2007-10-24 | Schering Corp | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS |
WO2007062266A2 (en) | 2005-11-28 | 2007-05-31 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
CA2633536A1 (en) | 2005-12-27 | 2007-07-05 | F. Hoffmann-La Roche Ag | Aryl-isoxazol-4-yl-imidazo[1, 5-a]pyridine derivatives |
WO2007074491A1 (en) | 2005-12-28 | 2007-07-05 | Universita Degli Studi Di Siena | HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
MX2008012617A (es) | 2006-03-31 | 2008-10-10 | Novartis Ag | Compuestos organicos. |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
MX2008015747A (es) | 2006-06-06 | 2008-12-19 | Schering Corp | Imidazopirazinas como inhibidores de la proteina quinasa. |
JP2009534396A (ja) | 2006-06-22 | 2009-09-24 | マリンクロッド・インコーポレイテッド | ピラジン誘導体および腎臓の監視におけるその使用 |
CA2655857C (en) | 2006-06-22 | 2014-12-02 | Mallinckrodt Inc. | Pyrazine derivatives with extended conjugation and uses thereof |
KR20090031544A (ko) | 2006-06-29 | 2009-03-26 | 쉐링 코포레이션 | 치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제 |
WO2008005423A1 (en) | 2006-07-03 | 2008-01-10 | Cambrex Charles City, Inc. | Improved method of making sufentanil |
WO2008005908A2 (en) | 2006-07-07 | 2008-01-10 | Forest Laboratories Holdings Limited | Pyridoimidazole derivatives |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
WO2008011557A2 (en) | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
US7563797B2 (en) | 2006-08-28 | 2009-07-21 | Forest Laboratories Holding Limited | Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands |
DE102006041292A1 (de) | 2006-09-01 | 2008-03-06 | Henkel Kgaa | Wasserstoffperoxid-Aktivierung mit N-Heterocyclen |
WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
ES2377821T3 (es) | 2006-10-11 | 2012-04-02 | Amgen Inc. | Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos. |
CN101646419A (zh) | 2006-11-08 | 2010-02-10 | 诺瓦瓦克斯股份有限公司 | 制备多相药物组合物的固体剂型的方法 |
WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
JP5572388B2 (ja) | 2006-11-22 | 2014-08-13 | インサイト・コーポレイション | キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン |
WO2008065198A1 (en) | 2006-12-01 | 2008-06-05 | Galapagos N.V. | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases |
WO2008079404A2 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
DK2118101T3 (da) | 2007-03-09 | 2013-01-02 | Probiodrug Ag | IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer |
DE102007012645A1 (de) | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
EP1972628A1 (en) | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as CNS active compounds |
US8829190B2 (en) | 2007-04-16 | 2014-09-09 | Leo Pharma A/S | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
WO2008130951A1 (en) | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
WO2008141249A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
JP5343845B2 (ja) | 2007-05-21 | 2013-11-13 | 東レ株式会社 | 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
MX2009013213A (es) | 2007-06-08 | 2010-03-30 | Abbott Lab | Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa. |
WO2008156614A2 (en) | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
CN101801966A (zh) | 2007-07-18 | 2010-08-11 | 诺瓦提斯公司 | 双环杂芳基化合物和它们作为激酶抑制剂的用途 |
AU2008282885A1 (en) | 2007-07-31 | 2009-02-05 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
US20090047336A1 (en) | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
FR2920091A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier. |
FR2920090A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier. |
KR20090022616A (ko) | 2007-08-31 | 2009-03-04 | 한올제약주식회사 | 베실산클로피도그렐 함유 경구투여용 약제 |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
HUE027696T2 (en) | 2007-10-12 | 2016-10-28 | Novartis Ag | Preparations containing sphingosine-1-phosphate (S1P) receptor modulators |
AU2008343062B2 (en) | 2007-12-19 | 2013-03-07 | Genentech, Inc. | 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
KR100988233B1 (ko) | 2007-12-26 | 2010-10-18 | 한미홀딩스 주식회사 | 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 |
UA101493C2 (ru) | 2008-03-11 | 2013-04-10 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak |
WO2009114180A1 (en) | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
EP2277881A4 (en) | 2008-04-18 | 2011-09-07 | Shionogi & Co | HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K |
DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
US8349210B2 (en) | 2008-06-27 | 2013-01-08 | Transitions Optical, Inc. | Mesogenic stabilizers |
WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
JP2010070503A (ja) | 2008-09-19 | 2010-04-02 | Daiichi Sankyo Co Ltd | 抗真菌作用2−アミノトリアゾロピリジン誘導体 |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010064020A1 (en) | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
CA2750517A1 (en) | 2009-02-04 | 2010-08-12 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
CA2749933A1 (en) | 2009-02-04 | 2010-08-12 | Supernus Pharmaceuticals, Inc. | Formulations of desvenlafaxine |
TR200900879A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler |
TR200900878A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
WO2010091824A1 (en) | 2009-02-13 | 2010-08-19 | Bayer Schering Pharma Aktiengesellschaft | Fused pyrimidines as akt inhibitors |
WO2010104307A2 (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
WO2010107404A1 (en) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
US8481732B2 (en) | 2009-03-20 | 2013-07-09 | Incyte Corporation | Substituted heterocyclic compounds |
DK2415771T3 (da) | 2009-03-31 | 2013-10-14 | Kissei Pharmaceutical | Indolizinderivat og anvendelse deraf til medicinske formål |
DK2419429T3 (da) | 2009-04-16 | 2014-06-23 | Ct Nac De Investigaciones Oncológicas Cnio | Imidazopyraziner som inhibitorer af proteinkinaser |
TWI461426B (zh) | 2009-05-27 | 2014-11-21 | Merck Sharp & Dohme | (二氫)咪唑並異〔5,1-a〕喹啉類 |
RU2011153723A (ru) | 2009-06-10 | 2013-07-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты н3 рецепторов гистамина и способы их применения |
WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
IN2012DN01961A (ja) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
AU2010284221B2 (en) | 2009-08-18 | 2016-09-22 | Casero, Robert A | (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2011033265A1 (en) | 2009-09-18 | 2011-03-24 | Almac Discovery Limited | Pharmaceutical compounds |
CA2812683C (en) | 2009-09-25 | 2017-10-10 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
US8614315B2 (en) | 2009-12-25 | 2013-12-24 | Mahmut Bilgic | Cefdinir and cefixime formulations and uses thereof |
CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
RU2576662C2 (ru) | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
WO2011113862A1 (en) | 2010-03-18 | 2011-09-22 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines |
BR112012025101B1 (pt) | 2010-04-02 | 2021-08-31 | Ogeda S.A. | Compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e medicamento compreendendo os mesmos |
MX2012012111A (es) | 2010-04-19 | 2013-05-30 | Oryzon Genomics Sa | Inhibidores de demetilasa-1 especifica de lisina y su uso. |
US8765820B2 (en) | 2010-04-20 | 2014-07-01 | Universita Degli Studi Di Roma “La Sapienza” | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 |
TW201144310A (en) | 2010-04-28 | 2011-12-16 | Daiichi Sankyo Co Ltd | [5,6] heterocyclic compound |
WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
KR101564806B1 (ko) | 2010-05-13 | 2015-10-30 | 암젠 인크 | Pde10 저해제로서 유용한 질소 헤테로시클릭 화합물 |
CN102247321A (zh) | 2010-05-20 | 2011-11-23 | 上海亚盛医药科技有限公司 | 一种阿朴棉子酚酮自乳化药物传递系统及其制备方法 |
WO2011149438A1 (en) | 2010-05-28 | 2011-12-01 | Mahmut Bilgic | Combination of antihypertensive agents |
CN102295642B (zh) | 2010-06-25 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途 |
BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
WO2012007345A2 (en) | 2010-07-12 | 2012-01-19 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-a]pyrimidines and -pyridines |
WO2012009475A1 (en) | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
CN101987082B (zh) | 2010-07-16 | 2013-04-03 | 钟术光 | 固体制剂及其制备方法 |
CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
RU2611437C2 (ru) * | 2010-07-29 | 2017-02-22 | Оризон Дженомикс С.А. | Ингибиторы деметилазы lsd1 на основе арилциклопропиламина и их применение в медицине |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
CN102397552B (zh) | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
CN103221412B (zh) | 2010-09-29 | 2015-08-19 | 橘生药品工业株式会社 | (氮杂)中氮茚衍生物及其药物用途 |
US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
JP2013540767A (ja) | 2010-10-07 | 2013-11-07 | ザ ジェイ. デヴィッド グラッドストーン インスティテューツ | 免疫不全ウイルス転写を調節するための組成物および方法 |
BR112013007604B1 (pt) | 2010-10-18 | 2018-06-05 | E.I. Du Pont De Nemours And Company | Composto, composição, método para controlar um nematoide parasitário e semente tratada |
KR20180069132A (ko) | 2010-10-21 | 2018-06-22 | 메디베이션 테크놀로지즈 엘엘씨 | 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염 |
EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
ES2650744T3 (es) | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Inhibidores de la caseína quinasa 1 delta (CK1delta) |
UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
EP2651945A1 (en) | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080234A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
EP2651950A1 (en) | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
ES2544609T3 (es) | 2010-12-17 | 2015-09-02 | Bayer Intellectual Property Gmbh | Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos |
TWI617559B (zh) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | 2-芳基咪唑并[1,2-b]嗒.2-苯基咪唑并[1,2-a]吡啶,和2-苯基咪唑并[1,2-a]吡衍生物 |
EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
WO2012100229A2 (en) | 2011-01-21 | 2012-07-26 | The General Hospital Corporation | Compositions and methods for cardiovascular disease |
US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
EA023143B1 (ru) | 2011-03-25 | 2016-04-29 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Замещенный циклопропиламин в качестве ингибитора lsd1 |
WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
US20140329833A1 (en) | 2011-05-19 | 2014-11-06 | Oryzon Genomics, S.A | Lysine demethylase inhibitors for inflammatory diseases or conditions |
US20140296255A1 (en) | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
CA2838311A1 (en) | 2011-06-07 | 2012-12-13 | SPAI Group Ltd. | Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof |
ES2560611T3 (es) | 2011-06-20 | 2016-02-22 | Incyte Holdings Corporation | Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK |
TW201311149A (zh) | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | 有害生物防治劑 |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
BR112014002939A2 (pt) | 2011-08-09 | 2017-03-01 | Takeda Pharmaceuticals Co | composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1 |
WO2013025805A1 (en) | 2011-08-15 | 2013-02-21 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
WO2013033688A1 (en) | 2011-09-01 | 2013-03-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
US9273343B2 (en) | 2011-09-02 | 2016-03-01 | Promega Corporation | Compounds and methods for assaying redox state of metabolically active cells and methods for measuring NAD(P)/NAD(P)H |
EP2906562B1 (en) | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
AU2012324803B9 (en) * | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
CL2014000988A1 (es) | 2011-10-20 | 2014-11-03 | Oryzon Genomics Sa | Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia. |
JP6046154B2 (ja) | 2011-10-20 | 2016-12-14 | オリソン ヘノミクス エセ. アー. | Lsd1阻害剤としての(ヘテロ)アリールシクロプロピルアミン化合物 |
ITMI20111971A1 (it) | 2011-10-28 | 2013-04-29 | Mesogenics Srl | Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico |
EP2785183B1 (en) | 2011-11-14 | 2018-12-19 | Merck Sharp & Dohme Corp. | Triazolopyridinone pde10 inhibitors |
EP2787990A4 (en) | 2011-12-05 | 2015-09-02 | Univ Brandeis | TREATMENT OF AMYLOID DOSE BY MEANS OF COMPOUNDS THAT REGULATE THE STABILIZATION OF RETROMERS |
WO2014096985A2 (en) | 2012-12-19 | 2014-06-26 | Wockhardt Limited | A stable aqueous composition comprising human insulin or an analogue or derivative thereof |
CN104159901B (zh) | 2012-03-07 | 2016-10-26 | 默克专利股份公司 | 三唑并吡嗪衍生物 |
CN102587054B (zh) | 2012-03-13 | 2014-05-07 | 机械科学研究总院先进制造技术研究中心 | 缸盖自动锁紧装置及包括该装置的筒子纱染色机 |
CN102579381B (zh) | 2012-03-30 | 2013-07-10 | 河南中帅医药科技发展有限公司 | 盐酸胍法辛缓释制剂及其制备方法 |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
US9815819B2 (en) | 2012-06-28 | 2017-11-14 | Novartis Ag | Complement pathway modulators and uses thereof |
CN102772444A (zh) | 2012-07-06 | 2012-11-14 | 周明千 | 中药超微破壁口服片剂饮片的加工方法 |
GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
ES2660051T3 (es) | 2012-09-28 | 2018-03-20 | Vanderbilt University | Compuestos heterocíclicos condensados como inhibidores selectivos de BMP |
SG11201502527UA (en) | 2012-10-05 | 2015-04-29 | Rigel Pharmaceuticals Inc | Gdf-8 inhibitors |
EP2907802B1 (en) | 2012-10-12 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
US9757379B2 (en) | 2012-11-14 | 2017-09-12 | The Board Of Regents Of The University Of Texas System | Inhibition of HIF-2α heterodimerization with HIF1β (ARNT) |
US9388123B2 (en) | 2012-11-28 | 2016-07-12 | Kyoto University | LSD1-selective inhibitor having lysine structure |
US9144555B2 (en) | 2012-11-30 | 2015-09-29 | Darlene E. McCord | Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
CN103933036B (zh) | 2013-01-23 | 2017-10-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途 |
EP2956441A4 (en) | 2013-02-18 | 2016-11-02 | Scripps Research Inst | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL |
US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
AU2014231768A1 (en) | 2013-03-13 | 2015-09-24 | Australian Nuclear Science And Technology Organisation | Transgenic non-human organisms with non-functional TSPO genes |
US20160045531A1 (en) | 2013-03-14 | 2016-02-18 | Epizyme, Inc. | Combination therapy for treating cancer |
US20140343118A1 (en) | 2013-03-14 | 2014-11-20 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
EP3003301B1 (en) | 2013-05-30 | 2021-02-24 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
SG10201710543PA (en) | 2013-06-19 | 2018-02-27 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
IL302299A (en) | 2013-06-21 | 2023-06-01 | Myokardia Inc | Pyrimidinedione compounds against cardiac disorders |
US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
DK3043778T3 (da) | 2013-09-13 | 2017-11-27 | Bayer Pharma AG | Farmaceutiske sammensætninger, der indeholder refametinib |
KR101568724B1 (ko) | 2013-11-13 | 2015-11-12 | 서울대학교산학협력단 | 신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도 |
MX2016007585A (es) | 2013-12-11 | 2016-12-16 | Celgene Quanticel Res Inc | Inhibidores de desmetilasa-1 especifica de lisina. |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
ES2901711T3 (es) | 2014-02-13 | 2022-03-23 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1,1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
EA028942B1 (ru) | 2014-04-02 | 2018-01-31 | Бристол-Майерс Сквибб Компани | Биарильные ингибиторы киназы |
EP2929884A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and h2-receptor antagonists |
US10130618B2 (en) | 2014-04-11 | 2018-11-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
TN2016000418A1 (en) | 2014-04-11 | 2018-04-04 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof. |
CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
WO2015181380A1 (en) | 2014-05-30 | 2015-12-03 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
CN104173313B (zh) | 2014-08-25 | 2017-05-17 | 杭州朱养心药业有限公司 | 利伐沙班片剂药物组合物 |
JP6653116B2 (ja) | 2014-08-27 | 2020-02-26 | 日本ケミファ株式会社 | オルメサルタンのプロドラッグ製剤 |
EP3204383B1 (en) | 2014-10-08 | 2020-11-18 | F.Hoffmann-La Roche Ag | Spirodiamine derivatives as aldosterone synthase inhibitors |
SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
TW201700453A (zh) | 2015-04-03 | 2017-01-01 | 必治妥美雅史谷比公司 | Ido抑制劑 |
TW201639854A (zh) | 2015-04-03 | 2016-11-16 | 木塔比利斯公司 | 雜環化合物及其用於預防或治療細菌感染的用途 |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
CN112656772B (zh) | 2015-10-15 | 2022-05-20 | 浙江东日药业有限公司 | 利伐沙班药物组合物 |
EP3397616B1 (en) | 2015-12-29 | 2020-06-10 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
JPWO2017130933A1 (ja) | 2016-01-25 | 2018-11-29 | 国立大学法人 熊本大学 | 神経変性疾患治療剤 |
AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
EP3570843A1 (en) | 2017-01-18 | 2019-11-27 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
CN109963854B (zh) | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
KR20210049090A (ko) | 2018-07-05 | 2021-05-04 | 인사이트 코포레이션 | A2a/a2b 억제제로서 융합된 피라진 유도체 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
-
2015
- 2015-02-12 ME MEP-2019-315A patent/ME03580B/me unknown
- 2015-02-12 NZ NZ723203A patent/NZ723203A/en unknown
- 2015-02-12 HU HUE15707007A patent/HUE045725T2/hu unknown
- 2015-02-12 AU AU2015217119A patent/AU2015217119C1/en active Active
- 2015-02-12 MY MYPI2016001463A patent/MY196877A/en unknown
- 2015-02-12 RS RS20191440A patent/RS59534B1/sr unknown
- 2015-02-12 CA CA2939081A patent/CA2939081C/en active Active
- 2015-02-12 KR KR1020167025066A patent/KR102352408B1/ko active IP Right Grant
- 2015-02-12 UA UAA201609399A patent/UA122389C2/uk unknown
- 2015-02-12 EP EP19190056.2A patent/EP3626714A1/en not_active Withdrawn
- 2015-02-12 MX MX2016010390A patent/MX2016010390A/es active IP Right Grant
- 2015-02-12 CN CN201580019205.7A patent/CN106488915B/zh active Active
- 2015-02-12 LT LT15707007T patent/LT3105226T/lt unknown
- 2015-02-12 TW TW108112023A patent/TWI720451B/zh active
- 2015-02-12 TW TW104104830A patent/TWI664164B/zh active
- 2015-02-12 JP JP2016551815A patent/JP6602779B2/ja active Active
- 2015-02-12 WO PCT/US2015/015635 patent/WO2015123424A1/en active Application Filing
- 2015-02-12 SI SI201530894T patent/SI3105226T1/sl unknown
- 2015-02-12 CR CR20200362A patent/CR20200362A/es unknown
- 2015-02-12 US US14/620,884 patent/US9493450B2/en active Active
- 2015-02-12 DK DK15707007.9T patent/DK3105226T3/da active
- 2015-02-12 BR BR112016018555-2A patent/BR112016018555B1/pt active IP Right Grant
- 2015-02-12 CR CR20160395A patent/CR20160395A/es unknown
- 2015-02-12 SG SG10201806846RA patent/SG10201806846RA/en unknown
- 2015-02-12 PT PT157070079T patent/PT3105226T/pt unknown
- 2015-02-12 EA EA201691594A patent/EA201691594A1/ru unknown
- 2015-02-12 EP EP15707007.9A patent/EP3105226B1/en active Active
- 2015-02-12 PE PE2016001467A patent/PE20161384A1/es unknown
- 2015-02-12 ES ES15707007T patent/ES2750956T3/es active Active
- 2015-02-12 SG SG11201606333VA patent/SG11201606333VA/en unknown
- 2015-02-12 PL PL15707007T patent/PL3105226T3/pl unknown
-
2016
- 2016-07-26 IL IL246950A patent/IL246950B/en active IP Right Grant
- 2016-08-04 PH PH12016501546A patent/PH12016501546A1/en unknown
- 2016-08-10 MX MX2020003702A patent/MX2020003702A/es unknown
- 2016-08-10 CL CL2016002021A patent/CL2016002021A1/es unknown
- 2016-09-09 EC ECIEPI201673171A patent/ECSP16073171A/es unknown
- 2016-10-07 US US15/288,605 patent/US9994546B2/en active Active
-
2018
- 2018-05-04 US US15/970,954 patent/US10676457B2/en active Active
-
2019
- 2019-06-17 AU AU2019204244A patent/AU2019204244B2/en active Active
- 2019-10-09 JP JP2019186168A patent/JP6781815B2/ja active Active
- 2019-11-08 HR HRP20192033TT patent/HRP20192033T1/hr unknown
- 2019-11-21 CY CY20191101225T patent/CY1122314T1/el unknown
-
2020
- 2020-05-01 US US16/864,304 patent/US11155532B2/en active Active
- 2020-09-13 IL IL277299A patent/IL277299B/en unknown
- 2020-10-16 JP JP2020174661A patent/JP2021011496A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020023529A5 (ja) | ||
JP2020019812A5 (ja) | ||
JP2017510555A5 (ja) | ||
HRP20192033T1 (hr) | Ciklopropilamini kao lsd1 inhibitori | |
CN109311868B (zh) | 用于治疗癌症和炎性疾病的化合物 | |
JP2015518894A5 (ja) | ||
HRP20192167T1 (hr) | Ciklopropilamini kao lsd1 inhibitori | |
JP2018505193A5 (ja) | ||
JP2011515462A5 (ja) | ||
BR112020008833A2 (pt) | moduladores da via de estresse integrada | |
JP2015500862A5 (ja) | ||
JP2017510554A5 (ja) | ||
CN107872977A (zh) | Irak4抑制剂与btk抑制剂的组合产品 | |
JP2009515852A (ja) | Egfr/her2インヒビターを含む癌の組み合わせ治療 | |
JP7328218B2 (ja) | タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤 | |
JP2017530999A5 (ja) | ||
BR112021003071A2 (pt) | composições especialmente formuladas de nintedanib e sais de nintedanib inalados | |
JP2012525332A5 (ja) | ||
AU2012292276A1 (en) | Pyridin-2(1H)-one derivatives as JAK inhibitors | |
JP2017508787A (ja) | 医薬化合物 | |
JP2004534010A5 (ja) | ||
JP2009515814A5 (ja) | ||
JP2016528298A5 (ja) | ||
CA2611474A1 (en) | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor | |
KR20130069603A (ko) | 종양 및 섬유증 질환 치료에서의 신규 병용 치료 |